Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

Benzinga · 1d ago
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.